Kingston Discusses BNT 162 B Vaccine, Study on Severe COVID Cases, and Potential Toxin Findings

Biotech Analyst Karen Kingston discussed key findings related to the Biologics License Application for the Pfizer-BioNTech COVID-19 vaccine, BNT 162 B.

• The experimental version includes optimized codons to improve antigen expression.
• A Philadelphia study found no detectable SARS-CoV-2 mRNA in severe COVID patients, leading researchers to investigate toxins.
• Findings suggest the presence of cobra venom, synthetic rabies virus, staphylococcal enterotoxin B, and HIV glycoprotein.
• The discussion concluded with an analysis of the patent abstract, describing the spike protein’s stabilization in a pre-fusion state